Please login to the form below
Creabilis names Catherine Moukheibir as chairman of the board
She has previously held roles at Ablynx, Movetis and Innate Pharma
Dermatology firm Creabilis has appointed Catherine Moukheibir as chairman of its board of directors.
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
Commenting on her appointment, Moukheibir said: “I am delighted to have been appointed to lead the Creabilis Board at this important time in the Company's development.
“The potential of CT327 in the treatment of pruritic conditions is a significant opportunity and the data reported so far demonstrates the power of Creabilis' pipeline and its unique low systemic exposure platform technology.”
Moukheibir has a wide range of experience in aligning corporate goals with financial strategy.
After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at Ablynx and member of the management board at Innate Pharma.
Last November, Moukheiber was also named as an observer to Zealand's board of directors.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Robust Review: COVID19 Assessment
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- The transatlantic opioid crisis
- WHO to test three more potential COVID-19 treatments
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
